Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II lenvatinib in recurrent/metastatic adenoid cystic carcinoma of salivary glands
2015-000693-35Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in adenoid cystic carcinoma (ACC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Objective response rate. Started Nov 2020; status: completed.
02
Drugs
lenvatinib
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on 2015-000693-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000693-35.